2-甲氧基-N-(2-苯基乙基)乙酰胺 | 133611-77-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲氧基-N-(2-苯基乙基)乙酰胺
• 英文名称: N-phenylethyl-2-methoxyacetamide
• 英文别名: N-Methoxyacetyl-2-phenylethylamine；N-phenylethylmethoxyacetamide；2-methoxy-N-(2-phenylethyl)acetamide
• CAS: 133611-77-5
• 化学式: C₁₁H₁₅NO₂
• mdl: MFCD00464954
• 分子量: 193.246
• InChiKey: GMCUTBZAYPXCOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 2-甲氧基-N-(2-苯基乙基)乙酰胺 在 硫酸 、 溶剂黄146 作用下， 反应 48.0h， 以73%的产率得到2-Methoxyacetyl-1,2,3,4-tetrahydroisoquinoline
  参考文献：
  名称：

  Improved Methods for the Synthesis of N-Acyltetrahydroisoquinolines

  摘要：

  One-pot procedures for the synthesis of N-acyltetrahydroisoquinolines have been developed from 2-phenylethylamines, acyl chlorides or carboxylic acids and aldehydes.

  DOI：

  10.1080/00397919208021138
• 作为产物：
  描述：

  2-苯乙胺 、 甲氧基乙酸 在 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 2-甲氧基-N-(2-苯基乙基)乙酰胺
  参考文献：
  名称：

  Pyrimidine derivatives and processes for the preparation thereof

  摘要：

  本发明涉及具有优异抗分泌活性的新型嘧啶衍生物的化学式(I)或其药学上可接受的盐，以及含有其作为活性成分的药物组合物，其新型中间体，以及其制备方法，其中：当A为哌啶-1-基或-NH-B时，其中B为C3-C4烷基，C3-C4烯基，C3-C7环烷基，C1-C3烷氧乙基，苯乙基，可以是取代或未取代的，3-三氟甲基苯甲基，1-萘甲基，4-甲基噻唑-2-基或4-苯基噻唑-2-基，R1为氢或甲基；而R2、R3、R4和R5为氢；或当A为化学式(II)的基团时；当R1为羟甲基或C1-C3烷氧甲基，R2、R3、R4、R5和R6为氢；而R7为氢或卤素；或当R1为氢或甲基，R7为氢或卤素；且R2、R3、R4、R5和R6中的一个或两个为羟基，甲氧基，或化学式(III)的基团，其中Z为C1-C4烷基，取代或未取代的C1-C4烯基，环烷基，苄氧基烷基，烷氧羰基烷基，吗啉甲基，哌啶甲基，4-取代哌嗪甲基，取代或未取代的苯基，萘基，取代或未取代的苄基，噻吩-2-基-甲基，1-取代吡咯啉-2-基或-NHR9，其中R8为氢，甲基，异丙基，苄基，苄氧甲基，甲硫乙基，苄氧羰基甲基，氨基甲基，氨基乙基，或1-苄基咪唑-4-基甲基，而R9为氢或叔丁氧羰基；其他为氢或甲基。

  公开号：

  US06352993B1

文献信息

• Antithrombotic amidinotetrahydropyridylalanine derivatives
  申请人：Pfizer Inc.

  公开号：US05798352A1

  公开（公告）日：1998-08-25

  This invention is directed to compounds of formula (I), ##STR1## pharmaceutically acceptable salts thereof, and pharmaceutically acceptable solvates of either entity, wherein Y is optionally monounsaturated C.sub.3 -C.sub.5 alkylene optionally substituted with C.sub.1 -C.sub.4 alkyl or methylene; R.sup.1 is H; C.sub.1 -C.sub.4 alkyl optionally substituted with C.sub.1 -C.sub.4 alkoxy, OH, NR.sup.5 R.sup.6, CONR.sup.5 R.sup.6, C.sub.3 -C.sub.6 cycloalkyl or aryl; or C.sub.3 -C.sub.6 alkenyl; R.sup.2 is H; C.sub.1 -C.sub.4 alkyl optionally substituted with C.sub.1 -C.sub.4 alkoxy, OH, NR.sup.5 R.sup.6, CONR.sup.5 R.sup.6, C.sub.3 -C.sub.6 cycloalkyl or aryl; or CONR.sup.5 R.sup.6 ; R.sup.3 and R.sup.4 are each independently selected from H; C.sub.1 -C.sub.4 alkyl optionally substituted with NR.sup.5 R.sup.6 ; C.sub.1 -C.sub.4 alkoxy; halo; CONR.sup.5 R.sup.6 and aryl; aryl is phenyl optionally substituted with one, two or three substituents independently selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, OH, halo and CF.sub.3 ; R.sup.5 and R.sup.6 are each independently selected from H and C.sub.1 -C.sub.4 alkyl; and m and n are each independently 1, 2 or 3; which are potent and selective thrombin inhibitors useful in the treatment of inter alia, deep vein thrombosis; reocclusion following thrombolytic therapy; chronic arterial obstruction; peripheral vascular disease; acute myocardial infarction; unstable angina; atrial fibrillation; thrombotic stroke; transient ischaemic attacks; restenosis and occlusion following angioplasty; or neurodegenerative disorders.

  本发明涉及化合物的结构式(I) ##STR1## 及其药学上可接受的盐和任一实体的药学上可接受的溶剂结晶体，其中Y是可选择地具有C.sub.3 -C.sub.5的不饱和的烷基，可选择地取代有C.sub.1 -C.sub.4烷基或亚甲基; R.sup.1是H; 可选择地取代有C.sub.1 -C.sub.4烷基的C.sub.1 -C.sub.4烷氧基、OH、NR.sup.5 R.sup.6、CONR.sup.5 R.sup.6、C.sub.3 -C.sub.6环烷基或芳基; 或C.sub.3 -C.sub.6烯基; R.sup.2是H; 可选择地取代有C.sub.1 -C.sub.4烷基的C.sub.1 -C.sub.4烷氧基、OH、NR.sup.5 R.sup.6、CONR.sup.5 R.sup.6、C.sub.3 -C.sub.6环烷基或芳基; 或CONR.sup.5 R.sup.6; R.sup.3和R.sup.4各自独立地选择自H; 可选择地取代有NR.sup.5 R.sup.6的C.sub.1 -C.sub.4烷基; C.sub.1 -C.sub.4烷氧基; 卤素; CONR.sup.5 R.sup.6和芳基; 芳基是苯基，可选择地取代有一个、两个或三个从C.sub.1 -C.sub.4烷基、C.sub.1 -C.sub.4烷氧基、OH、卤素和CF.sub.3中独立选择的取代基; R.sup.5和R.sup.6各自独立地选择自H和C.sub.1 -C.sub.4烷基; m和n各自独立地选择为1、2或3; 这些化合物是有效且选择性的凝血酶抑制剂，在治疗包括深静脉血栓形成、溶栓治疗后再闭塞、慢性动脉阻塞、周围血管疾病、急性心肌梗死、不稳定性心绞痛、心房颤动、血栓性中风、短暂性缺血发作、血管成形术后再狭窄和闭塞，或神经退行性疾病等方面有用。
• Antithrombotic amidinophenylalanine and amidinopyridylalanine derivatives
  申请人：Pfizer Inc.

  公开号：US05750520A1

  公开（公告）日：1998-05-12

  This invention relates to compounds of formula (I), ##STR1## pharmaceutically acceptable salt thereof, and pharmaceutically acceptable solvates of either entity, wherein X is CH or N; Y is optionally monousaturated C.sub.3 -C.sub.5 alkylene optionally substituted with C.sub.1 -C.sub.4 alkyl or methylene; R.sup.1 is H; C.sub.1 -C.sub.4 alkyl optionally substituted with C.sub.1 -C.sub.4 alkoxy, OH, NR.sup.5 R.sup.6, CONR.sup.5 R.sup.6, C.sub.3 -C.sub.6 cycloalkyl or aryl; or C.sub.3 -C.sub.6 alkenyl; R.sup.2 is H; C.sub.1 -C.sub.4 alkyl optionally substituted with C.sub.1 -C.sub.4 alkoxy, OH, NR.sup.5 R.sup.6, CONR.sup.5 R.sup.6, C.sub.3 -C.sub.6 cycloalkyl or aryl; or CONR.sup.5 R.sup.6 ; R.sup.3 and R.sup.4 are each independently selected from H; C.sub.1 -C.sub.4 alkyl optionally substituted with NR.sup.5 R.sup.6 ; C.sub.1 -C.sub.4 alkoxy; halo; CONR.sup.5 R.sup.6 and aryl; R.sup.5 and R.sup.6 are each independently selected from H and C.sub.1 -C.sub.4 alkyl; and m and n are each independently 1, 2 or 3; are potent and selective thrombin inhibitors useful in the treatment of, inter alia, deep vein thrombosis; reocclusion following thrombolytic therapy; chronic arterial obstruction; peripheral vascular disease; acute myocardial infarction; unstable angina; atrial fibrillation; thrombotic stroke; transient ischaemic attacks; restenosis and occlusion following angioplasty; or neurodegenerative disorders.

  本发明涉及式(I)的化合物，其中X为CH或N；Y为可选择的单不饱和C.sub.3-C.sub.5烷基，可选择地取代为C.sub.1-C.sub.4烷基或亚甲基；R.sup.1为H；C.sub.1-C.sub.4烷基，可选择地取代为C.sub.1-C.sub.4烷氧基，OH，NR.sup.5R.sup.6，CONR.sup.5R.sup.6，C.sub.3-C.sub.6环烷基或芳基；或C.sub.3-C.sub.6烯基；R.sup.2为H；C.sub.1-C.sub.4烷基，可选择地取代为C.sub.1-C.sub.4烷氧基，OH，NR.sup.5R.sup.6，CONR.sup.5R.sup.6，C.sub.3-C.sub.6环烷基或芳基；或CONR.sup.5R.sup.6；R.sup.3和R.sup.4各自独立地选自H；C.sub.1-C.sub.4烷基，可选择地取代为NR.sup.5R.sup.6；C.sub.1-C.sub.4烷氧基；卤素；CONR.sup.5R.sup.6和芳基；R.sup.5和R.sup.6各自独立地选自H和C.sub.1-C.sub.4烷基；m和n各自独立地为1、2或3；这些化合物是有效且选择性的凝血酶抑制剂，可用于治疗深静脉血栓形成等疾病。
• One-pot biocatalytic amine transaminase/acyl transferase cascade for aqueous formation of amides from aldehydes or ketones
  作者：Henrik Land、Peter Hendil-Forssell、Mats Martinelle、Per Berglund

  DOI：10.1039/c6cy00435k

  日期：——

  An efficient one-pot one-step biocatalytic amine transaminase/acyl transferase cascade for the formation of amides from the corresponding aldehydes and ketones in aqueous solution has been developed. N-Benzyl-2-methoxyacetamide has been synthesized utilizing the developed cascade with conversions up to 97%. The cascade was also evaluated for the synthesis of chiral amides.

  已经开发了一种有效的一锅一步生物催化胺转氨酶/酰基转移酶级联反应，用于从水溶液中的相应醛和酮形成酰胺。N-苄基-2-甲氧基乙酰胺已利用开发的级联反应合成，转化率高达97％。还评估了该级联的手性酰胺的合成。
• Venkov A. P., Lukanov L. K., Synth. Commun., 22 (1992) N 22, S 3235-3242
  作者：Venkov A. P., Lukanov L. K.

  DOI：——

  日期：——
• ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES
  申请人：Pfizer Limited

  公开号：EP0728132B1

  公开（公告）日：1997-07-16